tiprankstipranks
Trending News
More News >
Healios KK (JP:4593)
:4593
Japanese Market
Advertisement

Healios KK (4593) AI Stock Analysis

Compare
2 Followers

Top Page

JP:4593

Healios KK

(4593)

Rating:51Neutral
Price Target:
¥697.00
▼(-2.24%Downside)
The overall score is heavily impacted by the company's poor financial performance, despite strong technical indicators. The negative P/E ratio and lack of dividends further diminish the stock's attractiveness. Positive market momentum offers some optimism, but financial challenges require immediate attention.

Healios KK (4593) vs. iShares MSCI Japan ETF (EWJ)

Healios KK Business Overview & Revenue Model

Company DescriptionHealios KK (4593) is a pioneering biotechnology company based in Japan, focusing on the development of regenerative medicine and cell therapy products. The company primarily operates in the healthcare sector, leveraging advanced technologies to develop innovative treatments aimed at addressing unmet medical needs. Its core products are based on induced pluripotent stem cells (iPSCs), which have the potential to transform into various cell types, making them highly versatile for therapeutic applications. Healios KK is committed to advancing therapies that can significantly improve patient outcomes in areas such as ophthalmology and immunology.
How the Company Makes MoneyHealios KK generates revenue through the development and commercialization of its regenerative medicine and cell therapy products. The company collaborates with research institutions and pharmaceutical companies to advance its product pipeline, which includes therapies targeting retinal diseases and acute respiratory distress syndrome. Key revenue streams include licensing agreements, research and development collaborations, and potential sales of its proprietary cell-based therapies upon regulatory approval. Strategic partnerships and collaborations help the company to share the cost of development and access broader markets, thereby contributing to its earnings.

Healios KK Financial Statement Overview

Summary
Healios KK shows revenue growth potential but struggles with profitability, high leverage, and negative cash flows. The financial performance indicates significant challenges requiring strategic improvements.
Income Statement
35
Negative
Healios KK has shown consistent revenue growth, with a notable increase from ¥27M in 2020 to ¥588M TTM (Trailing-Twelve-Months) in 2025. However, the company struggles with profitability, as evidenced by negative EBIT and net profit margins over the years. The TTM gross profit margin stands at 61.73%, which is strong, yet the negative net profit margin of -743.54% indicates significant challenges in managing operational costs and other expenses.
Balance Sheet
40
Negative
The company's financial leverage is relatively high, with a debt-to-equity ratio of 1.35 TTM. While the equity ratio of 12.46% TTM is low, suggesting limited shareholder funding relative to total assets, the company maintains a solid cash position with negative net debt, indicating more cash and short-term investments than total debt. Return on equity remains negative, reflecting ongoing struggles in generating profits from shareholders' investments.
Cash Flow
30
Negative
Healios KK faces challenges in cash flow management, as indicated by negative operating and free cash flows. The TTM free cash flow of -¥2,278M shows deterioration compared to previous periods. The operating cash flow to net income ratio is negative, reflecting inefficiencies in converting revenue into cash flow. The free cash flow to net income ratio is also negative, underscoring the company's difficulty in generating cash from its operations.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue560.00M121.00M90.00M41.00M27.00M
Gross Profit432.00M108.00M90.00M41.00M27.00M
EBITDA-2.54B-2.70B-4.52B-3.61B-3.97B
Net Income-4.24B-3.82B-5.17B-4.91B-5.51B
Balance Sheet
Total Assets14.19B15.15B15.03B23.97B23.17B
Cash, Cash Equivalents and Short-Term Investments3.67B6.72B7.32B15.13B13.92B
Total Debt2.66B4.53B7.15B11.96B11.40B
Total Liabilities12.11B11.29B10.65B15.33B15.32B
Stockholders Equity2.06B3.86B4.38B8.64B7.84B
Cash Flow
Free Cash Flow-1.83B-2.85B-4.86B-5.39B-4.26B
Operating Cash Flow-1.82B-2.82B-4.60B-5.09B-3.94B
Investing Cash Flow-1.42B-1.12B-909.00M-736.00M-1.22B
Financing Cash Flow77.00M3.34B-2.50B6.99B803.00M

Healios KK Technical Analysis

Technical Analysis Sentiment
Positive
Last Price713.00
Price Trends
50DMA
468.54
Positive
100DMA
374.76
Positive
200DMA
299.35
Positive
Market Momentum
MACD
70.52
Negative
RSI
75.72
Negative
STOCH
87.84
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4593, the sentiment is Positive. The current price of 713 is above the 20-day moving average (MA) of 531.75, above the 50-day MA of 468.54, and above the 200-day MA of 299.35, indicating a bullish trend. The MACD of 70.52 indicates Negative momentum. The RSI at 75.72 is Negative, neither overbought nor oversold. The STOCH value of 87.84 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4593.

Healios KK Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
58
Neutral
¥25.38B
-2.34%-278.32%
52
Neutral
$7.60B0.11-62.95%2.07%16.16%0.31%
51
Neutral
¥78.04B
374.19%35.53%
49
Neutral
¥20.00B201.62
8.46%49.97%
47
Neutral
¥19.32B
-100.00%-1079.89%
46
Neutral
¥16.81B
-4.04%-0.88%
33
Underperform
¥51.21B
-12.82%-19.87%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:4593
Healios KK
678.00
497.00
274.59%
JP:4599
StemRIM Inc.
309.00
-145.00
-31.94%
JP:4894
Cuorips Inc.
6,130.00
-1,080.00
-14.98%
JP:4978
ReproCELL Inc.
216.00
76.00
54.29%
JP:7774
Japan Tissue Engineering Co., Ltd.
616.00
-58.00
-8.61%
JP:7776
CellSeed Inc.
485.00
-30.00
-5.83%

Healios KK Corporate Events

Healios K.K. Secures JPY 7 Billion Subsidy for CDMO Business Expansion
Jul 16, 2025

Healios K.K. has been selected for a JPY 7 billion subsidy under Japan’s METI program to support capital investment in regenerative, cell, and gene therapy manufacturing facilities. This funding will enable Healios to expand its CDMO business, enhancing its competitive edge in the global market by integrating advanced technologies and establishing a robust international platform. The initiative aligns with Japan’s industrial policy and aims to strengthen Healios’s position as a leader in regenerative medicine, fostering new partnerships and enhancing shareholder value.

The most recent analyst rating on (JP:4593) stock is a Buy with a Yen320.00 price target. To see the full list of analyst forecasts on Healios KK stock, see the JP:4593 Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 18, 2025